CA 19-9

The CA 19-9 test measures the carbohydrate antigen 19‑9 concentration in blood—a tumor marker commonly used to monitor pancreatic cancer and other gastrointestinal malignancies. With Touch Connect’s at‑home phlebotomy service in Dubai, a trained technician collects a small serum sample for laboratory analysis, offering convenient serial monitoring without clinic visits. Results (reported in U/mL) can help assess treatment response or detect recurrence but are not diagnostic alone—levels may rise in benign conditions such as cholestasis or pancreatitis and can be falsely low in Lewis‑antigen–negative individuals, so interpretation by your oncologist or gastroenterologist is essential.

• CA 19-9
• Sample Type: Serum
• Collection: At‑home phlebotomy (Dubai, UAE)
• Method: Chemiluminescent immunoassay (CLIA)
• Units / Reference Range: U/mL — 0–37

• Quantitative CA 19-9 serum measurement for monitoring pancreatic and other gastrointestinal cancers
• Convenient at-home blood draw by licensed phlebotomists across Dubai with samples processed in accredited diagnostic laboratories
• Useful for tracking treatment response and detecting possible recurrence when combined with imaging and clinical review
• Not a standalone diagnostic test—levels can be elevated in benign conditions (cholestasis, pancreatitis) and may be uninformative in Lewis‑negative individuals
• Secure, clinic-ready digital results delivery for your treating physician in Dubai

• CA 19-9 blood test for detecting and monitoring pancreatic and other gastrointestinal cancers
• Convenient at-home venous collection by trained phlebotomists with DHA‑accredited lab processing in Dubai
• Fast turnaround with clinically actionable results typically available within 24–48 hours
• Used for baseline assessment, monitoring treatment response, and surveillance for recurrence (not a standalone diagnostic test)
• Results interpreted alongside imaging and clinical findings; levels can be influenced by benign conditions or Lewis antigen status

• At‑home venous blood collection by DHA‑licensed phlebotomists with processing at accredited partner labs in Dubai
• Quantitative CA 19‑9 tumor marker assay to support early detection and monitoring of pancreatic and other gastrointestinal cancers
• Secure electronic delivery of results typically within 24–48 hours, with optional physician or nurse follow-up
• For surveillance and treatment monitoring only — not a standalone diagnostic test; clinical interpretation by your healthcare provider recommended